title: Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).
abstract: The activity of didemnin B, a natural product derived from the Caribbean Tunic was assessed in 16 patients with Glioblastoma multiforme. Didemnin B was administered intravenously by a short infusion at a dose of 4.3 mg/m2 and subsequently escalated to 6.3 mg/m2. No anti-tumor activity was observed. Toxicity consisted of fatigue, weakness, stomatitis, mild blood count changes, nausea and vomiting and occasional fever. Based on these results further studies with didemnin B in patients with Glioblastoma multiforme are not recommended.
authors.affiliation: New York Medical College, Division of Oncology/Hematology, Vallhalla, NY 10595, USA.
authors.forename: A
authors.initials: A
authors.lastname: Mittelman
authors.forename: H G
authors.initials: HG
authors.lastname: Chun
authors.forename: C
authors.initials: C
authors.lastname: Puccio
authors.forename: N
authors.initials: N
authors.lastname: Coombe
authors.forename: T
authors.initials: T
authors.lastname: Lansen
authors.forename: T
authors.initials: T
authors.lastname: Ahmed
mesh_terms: D000328:Adult; D000368:Aged; D000708:Anaplasia / Q000473:pathology / Q000517:prevention & control; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy*; D047630:Depsipeptides; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000009:adverse effects* / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C030051:didemnins